Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer

@inproceedings{Barton2012AssessmentOT,
  title={Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer},
  author={Sarah R Barton and Lila A Zabaglo and Roger P A'hern and Nicholas C. Turner and Tom Ferguson and Sarah O'Neill and Margaret Hills and Ian E. Smith and Mitch Dowsett},
  booktitle={British Journal of Cancer},
  year={2012}
}
Background:The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility in personalising breast cancer treatment in a clinical practice setting, through comparison with Adjuvant! Online (AoL) and the Nottingham Prognostic Index (NPI).Methods:We prospectively gathered clinicopathologic data for postmenopausal patients with hormone receptor-positive… CONTINUE READING
38 Citations
27 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

  • AC Wolff
  • J Clin Oncol
  • 2010

Similar Papers

Loading similar papers…